Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay.

CONCLUSIONS: Results suggest that molecular profiling with the 92-gene assay identifies a subset of ICI-eligible putative primary cancers in patients with CUP. We propose a treatment strategy based on available tests including clinicopathologic features, GEP, and ICI biomarkers of response. PMID: 32893931 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32893931?dopt=Abstract

Source: The Oncologist - September 6, 2020 Category: Cancer & Oncology Authors: Raghav K, Overman M, Poage GM, Soifer HS, Schnabel CA, Varadhachary GR Tags: Oncologist Source Type: research